Angle Plc - ANPCY STOCK NEWS

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced the issuance of 216,000 new Ordinary shares following the exercise of employee options. These shares will rank equally with existing shares. An application for their trading admission on AIM has been submitted, with trading anticipated to begin on 24 May 2021. Post-admission, the total number of Ordinary Shares will stand at 215,867,845. The company continues to develop its liquid biopsy technology, particularly the Parsortix system, which has shown promise in clinical studies for cancer diagnostics.

ANGLE plc (OTCQX:ANPCY) announced significant advancements from a study conducted by the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, focusing on triple negative breast cancer (TNBC). The study utilized ANGLE's Parsortix system to isolate circulating tumor cells (CTCs) concurrently with circulating tumor DNA (ctDNA) from a single blood sample. This method revealed multiple druggable targets associated with 12 FDA-approved treatment options. This research highlights the potential for non-invasive monitoring and precision therapy in TNBC, which is known for its limited treatment options and aggressive nature.

ANGLE plc (AIM: AGL OTCQX: ANPCY) has issued 203,333 new Ordinary shares following the exercise of employee options. The shares, valued at £0.10 each, will rank pari passu with existing shares. Admission to trading on AIM is expected to commence on 7 May 2021, increasing the total number of Ordinary Shares to 215,651,845. The company is known for its liquid biopsy technology, particularly its Parsortix system, which aims to transform cancer diagnostics and monitoring.

ANGLE plc has reported its preliminary results for the year ending December 31, 2020, highlighting significant operational and financial developments. The company made a full De Novo FDA submission for the Parsortix system aimed at capturing circulating tumor cells. Key achievements include the completion of patient enrollment for an ovarian cancer study and the signing of a large-scale contract with a pharmaceutical customer, potentially generating up to US$1.2 million in revenue. Financially, revenue increased to £0.8 million, while losses rose to £11.6 million.

ANGLE plc has completed patient enrolment in a 200-patient ovarian cancer clinical verification study at the University of Rochester. The study evaluates the effectiveness of ANGLE's Parsortix system and HyCEAD platform for detecting ovarian cancer through a simple blood test. The study aims to finalize data by Q2 2021 and report results in Q4 2021. If successful, ANGLE plans to launch the test as a laboratory-developed test (LDT) by year-end, potentially addressing a market worth up to $1.8 billion in the U.S. alone.

ANGLE has announced a significant contract potentially worth US$1.2 million over 18 months with a major pharmaceutical company to utilize its Parsortix system.

This contract marks the first large-scale application of Parsortix in cancer drug trials, focusing on prostate cancer and other solid tumors. The system, which captures circulating tumor cells (CTCs) for analysis, enables ongoing monitoring of patients during clinical trials, surpassing traditional tissue biopsies in providing vital insights into cancer treatment.

ANGLE plc (OTCQX:ANPCY), a leader in liquid biopsy technology, will release its preliminary results for the year ending December 31, 2020, on April 29, 2021. A virtual meeting for analysts will occur at 10:00 am BST on the same day. The Parsortix system, their flagship technology, allows for non-invasive cancer analysis and has demonstrated a high accuracy in clinical studies. ANGLE's ongoing advancements include FDA submissions for regulatory clearance and collaborations with major healthcare entities to expand its market presence.

ANGLE plc announced its Parsortix system's capabilities showcased at the AACR 2021 conference. Two poster presentations highlighted the efficacy of new assays: one for circulating tumor cells (CTCs) detection in cancer (showing 25-38% of CTCs had mesenchymal markers), and another assessing PD-L1 status in patients, indicating potential for personalized immunotherapy. The global PD-L1 inhibitor market is projected to reach $22 billion, growing over 40% annually. ANGLE is pursuing partnerships for clinical trials and has established labs in the UK and US.